DOCSLIB.ORG

United States Patent (10 ) Patent No.: US 10,471,211 B2 Rusch Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent (10 ) Patent No.: US 10,471,211 B2 Rusch Et Al US010471211B2 United States Patent (10 ) Patent No.: US 10,471,211 B2 Rusch et al. (45 ) Date of Patent: Nov. 12 , 2019 ( 54 ) MEDICAL DELIVERY DEVICE WITH A61M 2005/31506 ; A61M 2205/0216 ; LAMINATED STOPPER A61M 2205/0222 ; A61M 2205/0238 ; A61L 31/048 ( 71 ) Applicant: W.L. Gore & Associates, Inc., Newark , See application file for complete search history. DE (US ) ( 56 ) References Cited ( 72 ) Inventors : Greg Rusch , Newark , DE (US ) ; Robert C. Basham , Forest Hill , MD U.S. PATENT DOCUMENTS (US ) 5,374,473 A 12/1994 Knox et al . 5,708,044 A 1/1998 Branca ( 73 ) Assignee : W. L. Gore & Associates, Inc., 5,792,525 A 8/1998 Fuhr et al. Newark , DE (US ) ( Continued ) ( * ) Notice: Subject to any disclaimer , the term of this patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U.S.C. 154 (b ) by 0 days . WO WO2014 / 196057 12/2014 WO WO2015 /016170 2/2015 ( 21) Appl. No .: 15 /404,892 OTHER PUBLICATIONS ( 22 ) Filed : Jan. 12 , 2017 International Search Report PCT/ US2017 /013297 dated May 16 , (65 ) Prior Publication Data 2017 . US 2017/0203043 A1 Jul. 20 , 2017 Primary Examiner Lauren P Farrar Related U.S. Application Data ( 74 ) Attorney , Agent, or Firm — Amy L. Miller (60 ) Provisional application No.62 / 279,553, filed on Jan. ( 57 ) ABSTRACT 15 , 2016 . The present disclosure relates to a medical delivery device that includes a barrel having an inner surface , a plunger rod ( 51 ) Int. Cl. having a distal end inserted within the barrel , and a stopper A61M 5/315 ( 2006.01) attached to the distal end of the plunger rod and contacting A61L 31/04 ( 2006.01) at least a portion of the inner surface of the barrel . In at least A61M 5/31 ( 2006.01) one embodiment, the inner surface is hydrophilic . The (52 ) U.S. CI. stopper may include an elastomeric body, one or more CPC A61M 5/31505 (2013.01 ) ; A61L 31/048 fluoropolymer layers , and two or more ribs laminated with (2013.01 ) ; A61M 5/31513 ( 2013.01) ; A61M the one or more fluoropolymer layers . In some embodi 2005/3101 ( 2013.01) ; A61M 2005/31506 ments , the contact width between at least one rib having a ( 2013.01 ) ; A61M 2205/0216 (2013.01 ) ; sealing surface and the portion of the inner surface of the ( Continued ) barrel measured at a compressibility of greater than about (58 ) Field of Classification Search 7.9 % of the stopper is less than about 1.0 mm . CPC A61M 5/31511; A61M 5/31513 ; A61M 5/315 ; A61M 5/31505 ; A61M 2005/3101; 27 Claims, 6 Drawing Sheets 100 -125 150 130 US 10,471,211 B2 Page 2 ( 52 ) U.S. CI. CPC A61M 2205/0222 (2013.01 ) ; A61M 2205/0238 ( 2013.01 ) (56 ) References Cited U.S. PATENT DOCUMENTS 6,030,694 A 2/2000 Dolan et al . 6,541,589 B1 4/2003 Baillie 7,521,010 B2 4/2009 Kennedy et al. 7,531,611 B2 5/2009 Sabol et al. 8,637,144 B2 1/2014 Ford 8,658,707 B2 2/2014 Xu et al. 8,722,178 B2 5/2014 Ashmead et al . 9,139,669 B2 9/2015 Xu et al . 2011/0137263 A1 6/2011 Ashmead et al. 2012/0251748 A1 * 10/2012 Ashmead A61M 5/31513 428 / 34.7 2015/0148751 A1 * 5/2015 Yotsutsuji A61M 5/31513 604/218 2016/0015898 A1 * 1/2016 Jones A61M 5/31513 604/230 2016/0022918 Al 1/2016 Gunzel * cited by examiner U.S. Patent Nov. 12 , 2019 Sheet 1 of 6 US 10,471,211 B2 115 -15 130 20 45 40 60 50 30 35 55 95 85 105 100 25 120 FIG . 1 U.S. Patent Nov. 12 , 2019 Sheet 2 of 6 US 10,471,211 B2 21 140 130 125 FIG . 2 100 125 Itt 150 } 145 130 FIG . 3 U.S. Patent Nov. 12 , 2019 Sheet 3 of 6 US 10,471,211 B2 100 125 150 } 145 ???????? 130 160 FIG . 4 100 125 165 150 - 145 130 FIG . 5 U.S. Patent Nov. 12 , 2019 Sheet 4 of 6 US 10,471,211 B2 100 125 175 180 130 FIG . 6 100 -125 175 180 130 FIG . 7 U.S. Patent Nov. 12 , 2019 Sheet 5 of 6 US 10,471,211 B2 100 170 125 130 190 FIG . 8 100 125 170 175 180 130 195 FIG . 9 U.S. Patent Nov. 12 , 2019 Sheet 6 of 6 US 10,471,211 B2 100 225 ( x ) 220 ( c ) 230 (r ) (c ) 220 205 -230 240 220 210 FIG . 10A (c % ) = V x 100 100 215 225 (w ). obs ( ) -220 -230 -220 205 240 -230 130 220 240 210 FIG . 10B US 10,471,211 B2 1 2 MEDICAL DELIVERY DEVICE WITH ably low break loose and slide forces ( i.e. , low - friction LAMINATED STOPPER slidability ) but not so much contact that the fluoropolymer film is distorted to create leak paths that decrease air and FIELD liquid impermeability . 5 The present invention relates to a medical delivery device SUMMARY with a laminated stopper , and in particular , to a medical delivery device with a stopper laminated with a fluoropo One embodiment relates to a medical delivery device that lymer film . includes a barrel , a plunger rod having a distal end inserted 10 within the barrel , a stopper attached to the distal end of the BACKGROUND plunger rod and contacting at least a portion of the inner surface of the barrel. The stopper has an elastomeric body, Medical delivery devices such as syringes typically one or more fluoropolymer layers , and two or more ribs include a barrel, a plunger rod reciprocally movable in the laminated with the one or more fluoropolymer layers . A barrel, and a stopper attached to an end of the plunger rod . 15 contact width between at least one of the two or more ribs The stopper to be used for the syringe is typically air, and having a sealing surface and a portion of the inner surface of liquid impermeable while also possessing low - friction slid the barrel measured at a compressibility of greater than ability . Air and liquid impermeability is important for elimi about 7.9 % of the stopper is less than about 1.0 mm . In at nating liquid leakage within the barrel and the introduction least one embodiment, the barrel has a hydrophilic inner of air between an outer face of the stopper and an inner wall 20 surface . Optionally , the hydrophilic inner surface is bare of the barrel when charging or discharging the liquid inside glass ( e.g., free or substantially free of silicone oil ) . the syringe . Low - friction slidability is important for facili In some embodiments, the medical delivery device further tating the charging and discharging of the liquid inside the includes a sliding surface that is less than about 2.0 mm , syringe. In addition to these requirements , a medical which is calculated based on a sum of the contact widths syringe, in particular, must not, adversely affect any phar- 25 between at least one of the two or more ribs having a sealing maceutical composition such as biopharmaceuticals that surface and the portion of the inner surface of the barrel come in contact with the syringe ( e.g. , a pre - filled syringe measured at a compressibility of greater than about 7.9 % . comprising a pharmaceutical composition ). In some embodiments , at least one of: each rib of the two Stoppers for conventional syringes are commonly made or more ribs having a sealing surface includes a radius of of a rubber material such as natural rubber , isoprene rubber 30 curvature at an apex of each respective rib that is less than or styrene -butadiene rubber which may be vulcanized . about 0.22 mm ; and a ratio of a maximum outer diameter of Although this type of conventional stopper, has satisfactory all the ribs having a sealing surface to an inner diameter of air and liquid impermeability , it does not have good low the inner surface of the barrel is nominally greater than about friction slidability . Accordingly , silicone lubricants are typi 1.08 . cally applied to both the outer face of the stopper and the 35 In some embodiments , a maximum outer diameter of the inner wall of the barrel such that the stopper can slide within ribs having a sealing surface is greater than about 5.0 mm , the barrel. However , syringes comprising silicone lubricants an inner diameter of the inner surface of the barrel is cannot be used for pharmaceutical composition and the like nominally between about 4.65 and about 11.85 mm , and a because the silicone lubricant can cause inactivation or ratio of the maximum outer diameter of the ribs having a otherwise impact the efficacy of these pharmaceutical com- 40 sealing surface to an inner diameter of the inner surface of positions. Therefore , in order to maintain the stability of the the barrel is greater than about 1.08 . pharmaceutical composition , stoppers laminated with a fluo In another embodiment, a plunger rod includes a distal ropolymer film have been used . Since the air and liquid end that is insertable into a barrel and a stopper attached to impermeability of stoppers may also have an impact on the the distal end . In one or more embodiment, the barrel has a quality and stability of the pharmaceutical compositions , the 45 hydrophilic inner surface. The stopper is configured to stoppers laminated with a fluoropolymer film are required to contact at least a portion of the inner surface of the barrel.
Load more

Recommended publications
  • Print PDF Opens in a New Window
    CADTH ISSUES IN EMERGING HEALTH TECHNOLOGIES Informing Decisions About New Health Technologies Issue July 173 2018 Monoclonal Antibodies for Osteoarthritis of the Hip or Knee Image courtesy of iStock CADTH ISSUES IN EMERGING HEALTH TECHNOLOGIES 1 Authors: Sirjana Pant, Ke Xin Li, Melissa Severn Cite As: Monoclonal Antibodies for Osteoarthritis of the Hip or Knee. Ottawa: CADTH; 2018. (CADTH issues in emerging health technologies; issue 173). Acknowledgments: CADTH would like to acknowledge the contribution of Dr. Tom Appleton, MD, PhD, FRCPC, Assistant Professor, Rheumatologist; Department of Medicine, Department of Physiology and Pharmacology, The University of Western Ontario; Clinician Scientist, Lawson Health Research Institute; The Rheumatology Centre, St. Joseph’s Health Care London; for his review of the draft version of this bulletin. ISSN: 1488-6324 (online) Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy- makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.
    [Show full text]
  • WO 2015/063180 Al 7 May 2015 (07.05.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/063180 Al 7 May 2015 (07.05.2015) P O P C T (51) International Patent Classification: (74) Agent: WILLIAMS, Rachel; Novozymes Biopharma UK A61K 39/00 (2006.01) C07K 16/00 (2006.01) Ltd., Castle Court, 59 Castle Boulevard, Nottingham Not A61K 39/395 (2006.01) tinghamshire NG7 1FD (GB). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/EP2014/073261 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) International Filing Date: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 29 October 2014 (29.10.2014) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (26) Publication Language: English MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (30) Priority Data: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 13 190750.3 29 October 2013 (29. 10.2013) EP SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 14166865.7 2 May 2014 (02.05.2014) EP TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant: NOVOZYMES BIOPHARMA DK A S (84) Designated States (unless otherwise indicated, for every [DK/DK]; Krogshoejvej 36, DK-2880 Bagsvaerd (DK).
    [Show full text]
  • Lung Cancer Drugs in the Pipeline
    HemOnc today | JANUARY 10, 2016 | Healio.com/HemOnc 5 Lung Cancer Drugs in the Pipeline HEMONC TODAY presents this guide to drugs in phase 2 or phase 3 development for lung cancer-related indications. Clinicians can use this chart as a quick reference to learn about the status of those drugs that may be clinically significant to their practice. Generic name (Brand name, Manufacturer) Indication(s) Development status abemaciclib (Eli Lilly) non–small cell lung cancer phase 3 ABP 215 (Allergan/Amgen) non–small cell lung cancer (advanced disease) phase 3 ACP-196 (Acerta Pharma) non–small cell lung cancer (advanced disease) phase 2 ado-trastuzumab emtansine (Kadcyla, Genentech) non–small cell lung cancer (HER-2–positive disease) phase 2 afatinib (Gilotrif, Boehringer Ingelheim) lung cancer (squamous cell carcinoma) phase 3 aldoxorubicin (CytRx) small cell lung cancer phase 2 alectinib (Alecensa, Genentech) non–small cell lung cancer (second-line treatment of ALK-positive disease) phase 2 non–small cell lung cancer (first-line treatment of ALK-positive disease); phase 3 alisertib (Takeda) malignant mesothelioma, small cell lung cancer phase 2 avelumab (EMD Serono/Pfizer) non–small cell lung cancer phase 3 AZD9291 (AstraZeneca) non–small cell lung cancer (first-line treatment of advancedEGFR -positive disease; phase 3 second-line treatment of advanced EGFR-positive, T790M-positive disease) bavituximab (Peregrine Pharmaceuticals) non–small cell lung cancer (previously treated advanced/metastatic disease) phase 3 belinostat (Beleodaq, Spectrum
    [Show full text]
  • 18 December 2020 – to Date)
    (18 December 2020 – to date) MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965 (Gazette No. 1171, Notice No. 1002 dated 7 July 1965. Commencement date: 1 April 1966 [Proc. No. 94, Gazette No. 1413] SCHEDULES Government Notice 935 in Government Gazette 31387 dated 5 September 2008. Commencement date: 5 September 2008. As amended by: Government Notice R1230 in Government Gazette 32838 dated 31 December 2009. Commencement date: 31 December 2009. Government Notice R227 in Government Gazette 35149 dated 15 March 2012. Commencement date: 15 March 2012. Government Notice R674 in Government Gazette 36827 dated 13 September 2013. Commencement date: 13 September 2013. Government Notice R690 in Government Gazette 36850 dated 20 September 2013. Commencement date: 20 September 2013. Government Notice R104 in Government Gazette 37318 dated 11 February 2014. Commencement date: 11 February 2014. Government Notice R352 in Government Gazette 37622 dated 8 May 2014. Commencement date: 8 May 2014. Government Notice R234 in Government Gazette 38586 dated 20 March 2015. Commencement date: 20 March 2015. Government Notice 254 in Government Gazette 39815 dated 15 March 2016. Commencement date: 15 March 2016. Government Notice 620 in Government Gazette 40041 dated 3 June 2016. Commencement date: 3 June 2016. Prepared by: Page 2 of 199 Government Notice 748 in Government Gazette 41009 dated 28 July 2017. Commencement date: 28 July 2017. Government Notice 1261 in Government Gazette 41256 dated 17 November 2017. Commencement date: 17 November 2017. Government Notice R1098 in Government Gazette 41971 dated 12 October 2018. Commencement date: 12 October 2018. Government Notice R1262 in Government Gazette 42052 dated 23 November 2018.
    [Show full text]
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Curriculum Vitae: Daniel J
    CURRICULUM VITAE: DANIEL J. WALLACE, M.D., F.A.C.P., M.A.C.R. Up to date as of January 1, 2019 Personal: Address: 8750 Wilshire Blvd, Suite 350 Beverly Hills, CA 90211 Phone: (310) 652-0010 FAX: (310) 360-6219 E mail: [email protected] Education: University of Southern California, 2/67-6/70, BA Medicine, 1971. University of Southern California, 9/70-6/74, M.D, 1974. Postgraduate Training: 7/74-6/75 Medical Intern, Rhode Island (Brown University) Hospital, Providence, RI. 7/75-6/77 Medical Resident, Cedars-Sinai Medical Center, Los Angeles, CA. 7/77-6/79 Rheumatology Fellow, UCLA School of Medicine, Los Angeles, CA. Medical Boards and Licensure: Diplomate, National Board of Medical Examiners, 1975. Board Certified, American Board of Internal Medicine, 1978. Board Certified, Rheumatology subspecialty, 1982. California License: #G-30533. Present Appointments: Medical Director, Wallace Rheumatic Study Center Attune Health Affiliate, Beverly Hills, CA 90211 Attending Physician, Cedars-Sinai Medical Center, Los Angeles, 1979- Clinical Professor of Medicine, David Geffen School of Medicine at UCLA, 1995- Professor of Medicine, Cedars-Sinai Medical Center, 2012- Expert Reviewer, Medical Board of California, 2007- Associate Director, Rheumatology Fellowship Program, Cedars-Sinai Medical Center, 2010- Board of Governors, Cedars-Sinai Medical Center, 2016- Member, Medical Policy Committee, United Rheumatology, 2017- Honorary Appointments: Fellow, American College of Physicians (FACP) Fellow, American College of Rheumatology (FACR)
    [Show full text]
  • Fontolizumab, a Humanised Anti-Interferon C Antibody
    1131 INFLAMMATORY BOWEL DISEASE Gut: first published as 10.1136/gut.2005.079392 on 28 February 2006. Downloaded from Fontolizumab, a humanised anti-interferon c antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn’s disease D W Hommes, T L Mikhajlova, S Stoinov, D Sˇtimac, B Vucelic, J Lonovics, M Za´kuciova´, G D’Haens, G Van Assche, S Ba, S Lee, T Pearce ............................................................................................................................... Gut 2006;55:1131–1137. doi: 10.1136/gut.2005.079392 See end of article for Introduction: Interferon c is a potent proinflammatory cytokine implicated in the inflammation of Crohn’s authors’ affiliations ....................... disease (CD). We evaluated the safety and efficacy of fontolizumab, a humanised anti-interferon c antibody, in patients with moderate to severe CD. Correspondence to: Methods: A total of 133 patients with Crohn’s disease activity index (CDAI) scores between 250 and 450, Dr D W Hommes, Department inclusive, were randomised to receive placebo or fontolizumab 4 or 10 mg/kg. Forty two patients Gastroenterology and received one dose and 91 patients received two doses on days 0 and 28. Investigators and patients were Hepatology, Academic unaware of assignment. Study end points were safety, clinical response (decrease in CDAI of 100 points or Medical Centre, C2-111, ( Meibergdreef 9 1105 AZ, more), and remission (CDAI 150). Amsterdam, the Results: There was no statistically significant difference in the primary end point of the study (clinical Netherlands; response) between the fontolizumab and placebo groups after a single dose at day 28. However, patients d.w.hommes@ receiving two doses of fontolizumab demonstrated doubling in response rate at day 56 compared with amc.uva.nl placebo: 32% (9/28) versus 69% (22/32, p = 0.02) and 67% (21/31, p = 0.03) for the placebo, and 4 Revised version received and 10 mg/kg fontolizumab groups, respectively.
    [Show full text]
  • Understanding Understanding Non-Hodgkin Non-Hodgkin Lymphoma Lymphoma This Patient Guide Is Supported Through Unrestricted Educational Grants From
    Understanding Understanding Non-Hodgkin Non-Hodgkin Lymphoma Lymphoma This patient guide is supported through unrestricted educational grants from: A Guide for Patients, 8th Edition Survivors, and Loved Ones Contact the Lymphoma Research Foundation Helpline: (800) 500-9976 [email protected] Website: lymphoma.org Fall 2020 Lymphoma Research Foundation (LRF) Helpline and Clinical Trials FOCUS ON LYMPHOMA Information Service MOBILE APP CONTACT THE LRF HELPLINE The Lymphoma Research Foundation’s Trained staff are available to answer questions mobile app, Focus on Lymphoma, is a and provide support to patients, caregivers and great tool and resource for lymphoma healthcare professionals in any language. patients to manage their disease. Our support services include: Focus on Lymphoma is the fi rst mobile • Information on lymphoma, treatment options, app that provides patients and side effect management and current research fi ndings caregivers comprehensive content • Financial assistance for eligible patients and based on their lymphoma subtype and tools to help manage their diagnosis, referrals for additional fi nancial, legal and including a medication manager, doctor sessions tool and side effects tracker. insurance help • Clinical trial searches based on patient’s The Focus on Lymphoma mobile app was recently named Best App by PR News and diagnosis and treatment history is available for free download for iOS and Android devices in the Apple App Store • Support through LRF’s Lymphoma Support and Google Play. Network, a national one-to one volunteer patient peer program For further information on LRF’s award winning mobile app or any of our Monday through Friday programs and services, call the LRF Helpline toll free (800) 500-9976, 9:30 am − 7:30 pm Eastern Standard Time (EST) Toll-Free (800) 500-9976 email [email protected] or visit us at lymphoma.org.
    [Show full text]
  • New Biological Therapies: Introduction to the Basis of the Risk of Infection
    New biological therapies: introduction to the basis of the risk of infection Mario FERNÁNDEZ RUIZ, MD, PhD Unit of Infectious Diseases Hospital Universitario “12 de Octubre”, Madrid ESCMIDInstituto de Investigación eLibraryHospital “12 de Octubre” (i+12) © by author Transparency Declaration Over the last 24 months I have received honoraria for talks on behalf of • Astellas Pharma • Gillead Sciences • Roche • Sanofi • Qiagen Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author Paul Ehrlich (1854-1915) • “side-chain” theory (1897) • receptor-ligand concept (1900) • “magic bullet” theory • foundation for specific chemotherapy (1906) • Nobel Prize in Physiology and Medicine (1908) (together with Metchnikoff) Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author 1981: B-1 antibody (tositumomab) anti-CD20 monoclonal antibody 1997: FDA approval of rituximab for the treatment of relapsed or refractory CD20-positive NHL 2001: FDA approval of imatinib for the treatment of chronic myelogenous leukemia Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author Functional classification of targeted (biological) agents • Agents targeting soluble immune effector molecules • Agents targeting cell surface receptors
    [Show full text]
  • Journal of Cancer Biology and Therapeutics
    ISSN: 2379-5972 Research Article Journal of Cancer Biology and Therapeutics Administration of Beta-Emitting Anti-CD37 Radioimmunoconjugate Lutetium (177Lu) Lilotomab Satetraxetan as Weekly Multiple Injections Increases Maximum Tolerated Activity in Nude Mice with Non- Hodgkin Lymphoma Xenografts Heyerdahl H*, Repetto-Llamazares AHV and Dahle J Department of Research and Development, Nordic Nanovector ASA, Norway *Correspondence: Helen Heyerdahl, Department of Research and Development, Nordic Nanovector ASA, Kjelsåsveien 168 B, 0884 Oslo, Norway, Tel: +(47) 22 18 33 01; Fax: +(47) 22 58 00 07; E-mail: [email protected] Received: Apr 20, 2018; Accepted: Aug 23, 2018; Published: Aug 28, 2018 Abstract Lutetium (177Lu) lilotomab satetraxetan (177Lu-lilotomab) is a novel anti-CD37 radioimmunoconjugate (RIC) currently in Phase 2b clinical trial for treatment of non-Hodgkin lymphoma (NHL). The aim of the current study was to investigate tolerability and anti-tumor efficacy of multiple dosing of 177Lu-lilotomab in vivo. Nude mice with subcutaneous (s.c.) NHL (Ramos) xenografts were given 2, 3 or 4 weekly injections of 300 MBq/kg 177Lu-lilotomab or NaCl. Treatment tolerability was assessed by body weight, hematology and histopathological evaluation. A separate experiment in mice without xenografts was performed to collect long term toxicity data. Mice in this study were dosed more conservatively with the intention that all mice should survive until end of experiment and were administered 2 or 4 weekly injections of 200 MBq/kg 177Lu-lilotomab or NaCl. Total accumulated activity of 900 MBq/kg 177Lu-lilotomab given as three weekly injections was tolerated by nude mice with s.c. Ramos xenografts, which is 50 % higher than the maximum tolerated activity (MTA) of a single injection of 530-600 MBq/kg.
    [Show full text]
  • Version Introducing VHIO Foreword
    2017SCIENTIFIC REPORT Vall d'Hebron Institute of Oncology (VHIO) CELLEX CENTER C/Natzaret, 115 – 117 08035 Barcelona, Spain Tel. +34 93 254 34 50 www.vhio.net Direction: Amanda Wren Design: Parra estudio Photography: Katherin Wermke Vall d'Hebron Institute of Oncology (VHIO) | 2018 VHIO Scientific Report 2017 Index Scientific Report INTRODUCING VHIO CORE TECHNOLOGIES 02 Foreword 92 Cancer Genomics Group 08 2017: marking the next chapter of 94 Molecular Oncology Group VHIO's translational story 96 Proteomics Group 18 Scientific Productivity: research articles VHIO'S TRANSVERSAL CLINICAL 19 Selection of some of the most relevant TRIALS CORE SERVICES & UNITS articles by VHIO researchers published in 2017 100 Clinical Trials Office 25 A Golden Decade: reflecting on the 102 Research Unit for Molecular Therapy past 10 years of VHIO's translational of Cancer (UITM) – ”la Caixa” success story 104 Clinical Research Oncology Nurses 106 Clinical Research Oncology Pharmacy PRECLINICAL RESEARCH Unit 49 From the Director 50 Experimental Therapeutics Group RECENTLY INCORPORATED GROUPS 52 Growth Factors Group 110 Cellular Plasticity & Cancer Group 54 Mouse Models of Cancer Therapies 112 Experimental Hematology Group Group 114 Tumor Immunology 56 Tumor Biomarkers Group & Immunotherapy Group 116 Applied Genetics of Metastatic Cancer TRANSLATIONAL RESEARCH Group 61 From the Director 118 Chromatin Dynamics in Cancer Group 62 Gene Expression & Cancer Group 120 Prostate Cancer Translational Research Group 64 Stem Cells & Cancer Group 122 Radiomics Group CLINICAL
    [Show full text]
  • Roche/Genentech Managed RG7986 ADC R/R NHL CHU Chugai Managed IONIS IONIS Managed 74 Status As of January 28, 2016 PRO Proximagen Managed
    Roche 2015 results London, 28 January 2016 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected.
    [Show full text]